Villejuif

• Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended recruitment
  2023-509781-37-00 7 2021-04-12 Nectin-4 Expressing Advanced Malignancies.
• Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing c … Ended recruitment
  2024-511658-28-01 5 2021-04-06 primary sclerosing cholangitis
• Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, Unresectable ESCC Ended recruitment
  2023-506413-22-00 5 2021-03-31 Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended recruitment
  2023-507970-42-00 5 2021-03-31 PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
• An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance … Ended recruitment
  2022-502600-79-00 4 2021-03-16 Endometrial cancer
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended recruitment
  2023-507418-28-00 4 2021-03-15 Solid tumors
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended recruitment
  2022-502705-15-00 5 2021-03-08 High-risk muscle-invasive bladder cancer
• A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C … Ended recruitment
  2023-509604-15-00 3 2021-02-15 Advanced Renal Cell Carcinoma
• Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended recruitment
  2024-513659-34-00 9 2021-02-12 Relapsed/Refractory aggressive B-NHL
• Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended recruitment
  2024-512238-13-00 4 2021-02-10 Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer
• A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations Ended recruitment
  2024-515150-24-00 1 2021-01-19 Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid
• Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended recruitment
  2024-515944-22-00 4 2021-01-19 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended recruitment
  2023-503384-41-00 5 2020-12-22 Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended recruitment
  2023-506839-15-00 9 2020-12-21 Renal cell carcinoma
• First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterat … Ended recruitment
  2023-510450-16-00 1 2020-12-16 Phase 1: Advanced solid tumors harboring genetic alterations in MET
• GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac … Ended recruitment
  2024-510714-32-00 4 2020-12-10 Patiens with locally advanced/metastatic endometrial carcinoma or cerv
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub … Ended recruitment
  2023-508281-15-00 1 2020-11-10 Locally Advanced or Metastatic Solid Tumors
• This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in c … Ended recruitment
  2023-504491-15-00 1 2020-10-30 Human epidermal growth factor receptor (HER2)-Expressing Cancers
• Post-operative adjuvant treatment for HPV-positive tumours Ended recruitment
  2024-516673-68-00 5 2020-10-27 Human papillomavirus (HPV)-positive oropharyngeal cancer
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in … Ended recruitment
  2024-518506-41-00 9 2020-10-05 metastatic castrate resistant prostate cancer
• A study comparing the efficacy and safety of osimertinib when given in combination with chemotherapy versus osimertinib alone in patients wi … Ended recruitment
  2023-508800-39-00 5 2020-09-29 Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L85

Showing 649–672 of 961 trials